QualityStar, a physician-founded supplement company, is expanding globally with multi-benefit products designed to simplify ...

A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days ...

Aegis Capital Corp. is acting as the sole book-running manager for the Offering on a firm commitment basis. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman & Canoles, ...

Light-it, a leading digital health company, introduces Puppeteer, an AI-powered platform poised to redefine the patient-provider relationship. See how it's transforming how providers and patients ...

LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of ...

The Board of Directors of the Company has authorized a virtual meeting of its shareholders to be held on Friday, January 17, 2025, at 10:30 a.m. Eastern Standard Time to seek approval for several ...

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com ...

Knoxville, TN, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, proudly announces the appointment of ...

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity ...

Alkeus’ presentation, which will include new data from the company’s TEASE-3 study of gildeuretinol in early-stage patients with Stargardt disease, will be Tuesday, January 14, at 4:30 p.m. PST at The ...

LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders ...

About NXC-201 NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete ...